Search: onr:"swepub:oai:DiVA.org:liu-147782" >
Thromboembolism pro...
Thromboembolism prophylaxis in patients with Philadelphia-negative myeloproliferative neoplasms-Clinical practice among Nordic specialists
-
- Bjerrum, Ole Weis (author)
- Rigshosp, Denmark
-
- Samuelsson, Jan (author)
- Region Östergötland, Hematologiska kliniken US
-
- Ghanima, Waleed (author)
- Univ Oslo, Norway; Univ Oslo, Norway
-
show more...
-
- Kauppila, Marjut (author)
- Turku Univ Hosp, Finland
-
- Andersen, Christen Lykkegaard (author)
- Rigshosp, Denmark; Roskilde Hosp, Denmark
-
show less...
-
(creator_code:org_t)
- 2018-03-25
- 2018
- English.
-
In: European Journal of Haematology. - : WILEY. - 0902-4441 .- 1600-0609. ; 100:5, s. 475-478
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Background: Patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) have higher risks of developing thromboembolisms compared to the general population. International guidelines on the management of MPNs therefore include recommendations concerning thromboembolism prophylaxis. In clinical practice, strict adherence to guidelines may be challenging and dependent on factors such as physician experience, outpatient clinic setting, and access to therapy; however, no data exist on physician adherence or patient compliance to thromboembolism prophylaxis in MPNs. Objectives: The Nordic Myeloproliferative Neoplasm Study Group (NMPN) performed a survey among Nordic hematology specialists with the aim of documenting the implementation of international recommendations in a region of Northern Europe with similar healthcare systems. Results: The study showed that Nordic specialists managed their patients in accordance with international guidelines concerning medical intervention, but to a lesser degree regarding the management of additional cardiovascular risk factors. The survey also drew attention to the common clinical dilemma of combining antiaggregatory agents with vitamin K antagonists (VKA), or novel oral anticoagulants (NOAC), as well as phlebotomy limits in female polycythemia vera patients. Conclusions: The results of this study highlight the importance of considering all risk factors for thrombosis and an optimal collaboration with the primary healthcare sector.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Keyword
- clinical practice; expert opinion; myeloproliferative neoplasms; prophylaxis; thromboembolic complications
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database